ALLMedicine™ Hepatocellular Carcinoma Center
Research & Reviews 23,807 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112460
Journal of Hepatocellular Carcinoma; Zhao D, Zhang X et. al.
May 21st, 2022 - The aim of this study was to identify and validate novel biomarkers for distinguishing among hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), liver fibrosis/liver cirrhosis (LF/LC) and chronic hepatitis B (CHB). Transcriptomic seque...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112182
Journal of Hepatocellular Carcinoma; Zhang L, Zhang Y et. al.
May 21st, 2022 - RNA binding motif protein 3 (RBM3) has been reported to be dysregulated in various cancers and associated with tumor aggressiveness. Epithelial-mesenchymal transition (EMT) is an important biological process by which tumor cells acquire metastatic...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112180
Disease Markers; Wang Z, Rehman AU et. al.
May 21st, 2022 - The dysregulated PI3K/AKT/mTOR pathway acts as the main regulator of tumorigenesis in hepatocellular carcinoma (HCC). Here, we identify the prognostic significance of PI3K/AKT/mTOR pathway-associated genes (PAGs) as well as their putative signatur...
https://doi.org/10.1007/s00330-022-08852-x 10.1016/S1072-7515(00)00261-1 10.1001/archsurg.1995.01430020088017 10.1111/j.1572-0241.2002.06038.x 10.1136/gut.36.3.437 10.1007/s00330-016-4648-0 10.1002/hep.1840090413 10.1016/j.ejrad.2018.04.012 10.1148/radiol.12112452 10.3748/wjg.15.3298 10.1007/s00330-020-07313-7 10.1097/RCT.0000000000000389 10.1007/s00261-020-02834-7 10.1053/jhep.2003.50346 10.1002/hep.21669 10.1053/jhep.2001.22172 10.1186/2193-1801-2-367 10.1148/radiol.14141435 10.1088/0031-9155/57/6/1701 10.1259/bjr/31999821 10.1016/j.neuroimage.2008.10.040 10.1148/radiol.2015150887 10.1148/97.3.589 10.1016/S0928-4346(96)00325-8 10.1016/S1590-8658(02)80246-8 10.1007/s00261-017-1211-7
European Radiology; Tago K, Tsukada J et. al.
May 21st, 2022 - To compare the predictive ability of liver fibrosis (LF) by CT-volumetry (CTV) for liver and spleen and extracellular volume fraction (ECV) for liver in patients undergoing liver resection. We retrospectively analysed 90 consecutive patients who u...
https://doi.org/10.1371/journal.pone.0259727
PloS One; Manzoor S, Khalid M et. al.
May 21st, 2022 - Major HCV infections lead to chronic hepatitis, which results in progressive liver disease including fibrosis, cirrhosis and eventually hepatocellular carcinoma (HCC). P2X4 and P2X7 are most widely distributed receptors on hepatocytes. Full length...
Guidelines 35 results
https://doi.org/10.1053/j.gastro.2021.12.276
Gastroenterology Su GL, Altayar O et. al.
Feb 26th, 2022 - Hepatocellular carcinoma (HCC), the most common primary liver cancer, remains a deadly cancer, with an incidence that has tripled in the United States since 1980. In recent years, new systemic therapies for HCC have been approved and a critical as...
https://doi.org/10.1016/j.numecd.2021.04.028
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; , et. al.
Dec 21st, 2021 - Nonalcoholic fatty liver disease (NAFLD) is a common and emerging liver disease in adults, paralleling the epidemic of obesity and diabetes, and leading to worrisome events (hepatocellular carcinoma and end-stage liver disease). In the last years,...
https://doi.org/10.1016/j.prro.2021.09.004
Practical Radiation Oncology; Apisarnthanarax S, Barry A et. al.
Oct 25th, 2021 - This guideline provides evidence-based recommendations for the indications and technique-dose of external beam radiation therapy (EBRT) in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC). The American Society for Radiation...
https://doi.org/10.1016/j.clinre.2021.101771
Clinics and Research in Hepatology and Gastroenterology; Tran A, Shili-Masmoudi S et. al.
Aug 1st, 2021 - Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. Clinical care for patients with HCV-related liver disease has advanced considerably with developments in screening, diagnostic procedures to evaluate liver fibrosis and i...
https://doi.org/10.1016/j.clinre.2021.101774
Clinics and Research in Hepatology and Gastroenterology; Dumortier J, Besch C et. al.
Aug 1st, 2021 - The field of liver transplantation directly or indirectly embodies all liver diseases, in addition to specific ones related to organ rejection (cellular and humoral). The recommended non-invasive methods for determining the indication for liver tr...
Drugs 19 results see all →
Clinicaltrials.gov 678 results
https://clinicaltrials.gov/ct2/show/NCT05003895
May 20th, 2022 - Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the second leading cause of cancer-associated mortality with an average life expectancy of 6-9 months Despite the success of several studies showing efficacy ...
https://clinicaltrials.gov/ct2/show/NCT03778957
May 20th, 2022 - This is a randomized, double-blind, placebo-controlled, multicenter, global Phase III study to determine the efficacy and safety of transarterial chemoembolization (TACE) treatment in combination with durvalumab monotherapy or TACE given with durv...
https://clinicaltrials.gov/ct2/show/NCT02649868
May 20th, 2022 - Background: Hepatocellular Carcinoma (HCC) is the 3rd most common cause of cancer globally with an increasing incidence worldwide. Management of hepatic malignancies from primary Hepatocellular Carcinoma (HCC) or metastatic disease involves a mult...
https://clinicaltrials.gov/ct2/show/NCT01556490
May 20th, 2022 - The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All patients receive the standard-of-care sorafenib with or without ...
https://clinicaltrials.gov/ct2/show/NCT04770896
May 18th, 2022 - This is a Phase III, open-label, multicenter, randomized, two-arm study designed to evaluate the efficacy and safety of atezolizumab plus either lenvatinib or sorafenib versus lenvatinib or sorafenib alone in participants with locally advanced or ...
News 1,224 results
https://www.mdedge.com/gihepnews/article/254679/hepatocellular-carcinoma/tips-plus-sequential-systemic-therapy-shows
May 17th, 2022 - Key clinical point: Transjugular intrahepatic portosystemic shunt (TIPS) plus sequential systemic therapy is safe and feasible for treating portal vein tumor thrombus (PVTT)-related symptomatic portal hypertension (SPH) in advanced hepatocellular.
https://www.mdedge.com/gihepnews/article/254678/hepatocellular-carcinoma/hcc-incidence-after-successful-daa-therapy
May 17th, 2022 - Key clinical point: Among patients with hepatitis C virus (HCV) who achieved a sustained virologic response (SVR) after direct-acting antiviral (DAA) therapy, those with cirrhosis showed an extremely high incidence of hepatocellular carcinoma (HCC.
https://www.mdedge.com/gihepnews/article/254673/hepatocellular-carcinoma/laparoscopic-anatomic-hepatectomy-achieves-better
May 17th, 2022 - Key clinical point: As laparoscopic anatomical hepatectomy (LAH) is associated with increased disease-free survival (DFS) and comparable long-term overall survival (OS) and postoperative complications compared with non-anatomical hepatectomy (LNAH.
https://www.mdedge.com/gihepnews/article/254672/hepatocellular-carcinoma/does-imaging-surveillance-intensity-govern
May 17th, 2022 - Key clinical point: Compared with the standard ultrasonography (US)-based imaging surveillance for hepatocellular carcinoma (HCC), intensive surveillance using alternative computed tomography (CT)/magnetic resonance imaging (MRI) in addition to US.
https://www.mdedge.com/internalmedicine/article/254344/gastroenterology/deep-learning-system-outmatches-pathologists
Will Pass
May 4th, 2022 - A new deep learning system can classify hepatocellular nodular lesions (HNLs) via whole-slide images, improving risk stratification of patients and diagnostic rate of hepatocellular carcinoma (HCC), according to investigators. While the model requ.
